Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The aim of this study is to validate uHear™, an iOS-based tool, as a screening tool to detect significant hearing impairment as part of a comprehensive geriatric assessment in patients aged 70 years and older. The pass or fail screening cut-off is defined as having two or more consecutive hearing grades starting from the moderate-severe threshold zone ranging from 0.5 - 2.0 kHz.

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02174055` - Identifying and Measuring Depression in Older Cancer Patients

NCT number	NCT02662998
Study type	Observational
Source	General Hospital Groeninge
Contact
Status	Completed
Phase	N/A
Start date	January 2016
Completion date	September 2016

Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS — UHEAR-BIS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms